Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer》.pdfVIP

下载本文档

14
0
约5.63万字
约 6页
2015-11-18 发布于河南
举报
版权申诉

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer》.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer》.pdf

Radiotherapy and Oncology 114 (2015) 161–166 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.th Phase II trial Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer Yong Bao a,1,⇑, Fang Peng b,1, Qi-Chao Zhou a,1, Zhong-Hua Yu c, Jian-Cheng Li d, Zhi-Bin Cheng e, f a g g h g c Long Chen , Xiao Hu , Yuan-Yuan Chen , Jin Wang , Yan Wang , Hong-Lian Ma , Zu-Min Xu , Ru-Biao Lu a, Xiao-Wu Deng a, Ming Chen a,1,⇑ a Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China; b Department of Radiation Oncology, The First Afﬁliated Hospital, Sun Yat-Sen University, Guangzhou; c Cancer Center, The Afﬁliated Hospital of Guangdong Medical College, Zhanjiang; d Department of Radiation Oncology, Fujian Provincial Tumor Hospital, Fuzhou; e Department of Radiation Oncology, The Fifth Afﬁliated Hospital of Sun Yat-Sen University, Zhuhai; f Department of Radiation Oncology, The Afﬁliated Tumor Hospital of Guangxi Medical University, Nanning; g Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou; and h Department of Radiation Oncology, Guangzhou General Hospital of Guangzhou Military Command, China a r t i c l e i n f o a b s t r a c t Article history: Purpose: The objective of th